Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 22 Precursor Cell Lymphoblastic Leukemia-Lymphoma 19 Myelodysplastic Syndromes 17 Multiple Myeloma 12 Ovarian Neoplasms 9 Recurrence 8 Lymphoma, B-Cell 8 Pancreatic Neoplasms 7 Lymphoma, Non-Hodgkin 7 Lymphoma 7 Hodgkin Disease 7 Burkitt Lymphoma 7 Colorectal Neoplasms 6 Myeloproliferative Disorders 5 Leukemia, Myelomonocytic, Chronic 5 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5 Leukemia, Biphenotypic, Acute 5 Stomach Neoplasms 4 Lymphoma, Mantle-Cell 4 Lymphoma, Large B-Cell, Diffuse 4 Leukemia 4 Hematologic Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Urogenital Neoplasms 3 Triple Negative Breast Neoplasms 3 Sarcoma 3 Osteosarcoma 3 Melanoma 3 Lymphoma, Follicular 3 Leukemia, B-Cell 3

Interventions

lifileucel 1 fludarabine phosphate 1 fludarabine 1 Nivolumab 1 Iodized Oil 1 Ethiodized Oil 1 Cyclophosphamide 1 Carmustine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Uveal Melanoma × fludarabine × 30 days × Clear all

NCT07627698 2026-06-04

DUET-MEL

Beijing Biotech

Phase 1/2 Recruiting

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡